Overview


According to FutureWise analysis the market for alkylating agents is expected to reach US$ 7.96 billion by 2031 at a CAGR of 3.60%.

Alkylating agents comprise a class of antineoplastic or anticancer medications that exert their effects by impeding the transcription of DNA into RNA, consequently halting the synthesis of proteins. These agents replace hydrogen atoms in DNA with alkyl groups, creating cross-links within the DNA chain. This results in cytotoxic, mutagenic, and carcinogenic repercussions. While this action is universal across all cells, it primarily impacts rapidly dividing cells, which lack the time for adequate DNA repair. Cancer cells, among the fastest splitting, bear the brunt of this impact. Nevertheless, other swiftly dividing cells, like those in hematopoietic, reproductive, and endothelial tissues, are also affected. This accounts for the prevalent side effects of alkylating agents, including anaemia, pancytopenia, amenorrhea, impaired spermatogenesis, intestinal mucosal damage, alopecia, and an elevated risk of developing malignancies. Ultimately, the alkylation process results in misinterpretation of the DNA code, inhibiting the synthesis of DNA, RNA, and proteins and prompting programmed cell death (apoptosis) in rapidly proliferating tumour cells.

While all alkylating agents entail significant toxicities, their primary impact is on the bone marrow and gastrointestinal tract. Many of these agents have demonstrated the potential to induce temporary elevations in serum aminotransferase levels in a subset of patients. It's noteworthy that when administered in high doses, alkylating agents can lead to sinusoidal obstruction syndrome (veno-occlusive disease) and nodular regenerative hyperplasia with prolonged use. These hepatic effects are typically dose-dependent and may arise from direct toxicity.

FutureWise Market Research has published a report that provides an insightful analysis of Alkylating Agents Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Alkylating Agents Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • AstraZeneca
  • Johnson and Johnson Private Limited
  • MerckCo., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin
  • Apotex, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Amneal Pharmaceuticals, Llc.
  • Aspen Holdings
  • Bausch Health Companies, Inc.
  • Alvogen
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals, plc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

On the driver side, the market for alkylating agents is significantly influenced by the high cancer incidence. According to World Health Organization (WHO) data, Africa, Asia, and south-central America account for more than 60% of cancer cases. By 2023, cancer cases are expected to reach 22 million. Various cancers such as Lung, liver, breast, colorectal, and stomach cancer are among the most occurring cancers, thus propelling the market growth. Another significant factor influencing the market growth in the expansion of healthcare infrastructure is the funds raised by the government organization, which is impacting the market growth. Moreover, an increase in the number of research and development, investment for the development of advanced technologies, and an increase in the number of emerging markets are providing great opportunities.

However, the high drug development and distribution cost is a significant factor restraining the market's growth. The need for skilled professionals and healthcare infrastructure will affect the market growth. In addition, side effects caused by the alkylating agents often act as restraints for market growth. Specific regulatory challenges are also faced by the alkylating market, which depletes the revenue of the market.

By Drug Class

  • Nitrogen Mustards
  • Bendamustine
  • Chlorambucil
  • Cyclophosphamide
  • Ifosfamide
  • Mechlorethamine
  • Melphalan
  • Nitrosoureas
  • Carmustine
  • Lomustine
  • Streptozocin
  • Alkyl Sulfonates
  • Busulfan
  • Triazines
  • Dacarbazine
  • Temozolomide
  • Ethylenimines
  • Altretamine
  • Thiotepa
  • Others

By Therapy Area

  • Oncology
  • Immunology
  • Ophthalmology
  • Dermatology
  • Gastroenterology
  • Urology
  • Others

By Route of Administration

  • Oral
  • Intravenous

By End User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process. 

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America accounts for the largest market share due to the well-established health infrastructure, early adoption of technological advancements, high healthcare expenditure, increased demand for disease-specific treatment, and surging prevalence of chronic disease will further propel the market. Whereas Asia-Pacific is expected to grow in the forecast period due to a surge in disposable income and favourable regulatory guidelines, expanded access to healthcare services and improvised healthcare infrastructure are driving the market growth in this region. In addition, government initiatives are playing a significant role in raising funds and promoting advanced healthcare technologies.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Alkylating Agents Market By Drug Class, By Therapy Area, By Route of Administration, By End User, By Distribution Channels and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Alkylating Agents Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Alkylating Agents Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Alkylating Agents Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Alkylating Agents Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    • 1. Nitrogen Mustards
      2. Bendamustine
      3. Chlorambucil
      4. Cyclophosphamide
      5. Ifosfamide
      6. Mechlorethamine
      7. Melphalan
      8. Nitrosoureas
      9. Carmustine
      10. Lomustine
      11. Streptozocin
      12. Alkyl Sulfonates
      13. Busulfan
      14. Triazines
      15. Dacarbazine
      16. Temozolomide
      17. Ethylenimines
      18. Altretamine
      19. Thiotepa
      20. Others

  • 8.   Alkylating Agents Market, By Therapy Area Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oncology
        2. Immunology
        3. Ophthalmology
        4. Dermatology
        5. Gastroenterology
        6. Urology
        7. Others

  • 9.   Alkylating Agents Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Intravenous

  • 10.   Alkylating Agents Market, By End Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 11.   Alkylating Agents Market, By Distribution Channels Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 12.   North America Alkylating Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Alkylating Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Alkylating Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Alkylating Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. GlaxoSmithKline plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novartis AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Mylan N.V.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Teva Pharmaceutical Industries Ltd.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Sanofi
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. AstraZeneca
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Johnson & Johnson Private Limited
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Merck & Co., Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. F. Hoffmann-La Roche Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Sun Pharmaceutical Industries Ltd.
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Lupin
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
        13. Apotex, Inc.
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. Dr. Reddy's Laboratories Ltd.
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Amneal Pharmaceuticals, Llc
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
         16. Aspen Holdings
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
        17. Bausch Health Companies Inc.
          17.1. Company Overview
          17.2. Product Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17.5. Strategic Overview
          18. Alvogen
          18.1. Company Overview
          18.2. Product Portfolio
          18.3. SWOT Analysis
          18.4. Financial Overview
          18.5. Strategic Overview
         19. Fresenius Kabi AG
          19.1. Company Overview
          19.2. Product Portfolio
          19.3. SWOT Analysis
          19.4. Financial Overview
          19.5. Strategic Overview
        20. Hikma Pharmaceuticals, Plc.
          20.1. Company Overview
          20.2. Product Portfolio
          20.3. SWOT Analysis
          20.4. Financial Overview
          20.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients